SML3523

Solriamfetol hydrochloride

Name: Solriamfetol hydrochloride
Brand: SIGMA

≥98% (HPLC), Dual dopamine and norepinephrine reuptake inhibitor, powder

Synonym(s):

(2R)-2-Amino-3-phenylpropyl carbamate hydrochloride, (R)-2-amino-3-phenylpropylcarbamate hydrochloride, ADX-N 05, ADX-N05, JZP 110, JZP-110

Slide 1 of 1

Select a Size

Pricing and availability is not currently available.

About This Item

Empirical Formula (Hill Notation):

C₁₀H₁₄N₂O₂ ·HCl

CAS Number:

178429-65-7

Molecular Weight:

230.69

UNSPSC Code:

12352200

NACRES:

NA.04

MDL number:

MFCD30724951

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Key Documents

View All Documentation

Product Name

Solriamfetol hydrochloride, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

drug control

USDEA Schedule IV

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	SML2784	SML0897	T0202
Sigma-Aldrich SML3523 Solriamfetol hydrochloride	Sigma-Aldrich SML2784 CMPD101 hydrochloride	Sigma-Aldrich SML0897 ALX 5407 hydrochloride	Sigma-Aldrich T0202 Tocainide hydrochloride
form powder	form powder	form powder	form solid
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
drug control USDEA Schedule IV	drug control -	drug control -	drug control -
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
solubility DMSO: 2 mg/mL, clear	solubility DMSO: 2 mg/mL, clear	solubility DMSO: 5 mg/mL, clear (warmed)	solubility DMSO: >20 mg/mL, H₂O: ≥5 mg/mL

Biochem/physiol Actions

Potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of DA and NE in vivo

Solriamfetol (JZP-110) is a potent and selective dual reuptake inhibitor at dopamine and norepinephrine transporters that increases extracellular levels of dopamine and norepinephrine in vivo. Solriamfetol is a wake-promoting agent.

Disclaimer

Hygroscopic

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.

Michelle G Baladi et al.

The Journal of pharmacology and experimental therapeutics, 366(2), 367-376 (2018-06-13)

Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration-approved drugs that act

Investigational therapies for the treatment of narcolepsy.

Stefano de Biase et al.

Expert opinion on investigational drugs, 26(8), 953-963 (2017-07-21)

Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. While non-pharmacological treatments are sometimes helpful, more than 90% of narcoleptic patients require a pharmacological treatment.

Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.

Richard K Bogan et al.

Sleep medicine, 16(9), 1102-1108 (2015-08-25)

JZP-110 is a wake-promoting agent with dopaminergic and noradrenergic activity. This double-blind, crossover study, randomized adults with narcolepsy with or without cataplexy (N = 33) to placebo or JZP-110 at 150 mg/day (weeks 1 and 3) increased to 300 mg/day (weeks 2 and 4).

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service